Table 1.

gBRCAm prevalence by region of enrollment (FAS)

	Asia (N = 104)	Europe (N = 199)	North America (N = 33)	Australia/Oceania (N = 5)	FAS (N = 341)
Positive for a gBRCAm, n (% [95% CI])	11 (10.6 [5.4, 18.1])	18 (9.0 [5.4, 13.9])	3 (9.1 [1.9, 24.3])	1 (20.0 [0.5, 71.6])	33 (9.7 [6.8, 13.3])
gBRCA1m only, n (% [95% CI])	6 (5.8 [2.1, 12.1])	10 (5.0 [2.4, 9.0])	0 (0.0 [0.0, 10.6])	0 (0.0 [0.0, 52.2])	16 (4.7 [2.7, 7.5])
gBRCA2m only, n (% [95% CI])	5 (4.8 [1.6, 10.9])	6 (3.0 [1.1, 6.4])	1 (3.0 [0.1, 15.8])	0 (0.0 [0.0, 52.2])	12 (3.5 [1.8, 6.1])
Both gBRCA1m and gBRCA2m, n (% [95% CI])	0 (0.0 [0.0, 3.5])	2 (1.0 [0.1, 3.6])	2 (6.1 [0.7, 20.2])	1 (20.0 [0.5, 71.6])	5 (1.5 [0.5, 3.4])

BRCA breast cancer susceptibility gene, CI confidence interval, FAS full analysis set, gBRCAm germline BRCA mutation